1
|
Jochems ACC, Muñoz Maniega S, Clancy U, Arteaga C, Jaime Garcia D, Chappell FM, Hewins W, Locherty R, Backhouse EV, Barclay G, Jardine C, McIntyre D, Gerrish I, Kampaite A, Sakka E, Valdés Hernández M, Wiseman S, Bastin ME, Stringer MS, Thrippleton MJ, Doubal FN, Wardlaw JM. Magnetic Resonance Imaging Tissue Signatures Associated With White Matter Changes Due to Sporadic Cerebral Small Vessel Disease Indicate That White Matter Hyperintensities Can Regress. J Am Heart Assoc 2024; 13:e032259. [PMID: 38293936 PMCID: PMC11056146 DOI: 10.1161/jaha.123.032259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 12/21/2023] [Indexed: 02/01/2024]
Abstract
BACKGROUND White matter hyperintensities (WMHs) might regress and progress contemporaneously, but we know little about underlying mechanisms. We examined WMH change and underlying quantitative magnetic resonance imaging tissue measures over 1 year in patients with minor ischemic stroke with sporadic cerebral small vessel disease. METHODS AND RESULTS We defined areas of stable normal-appearing white matter, stable WMHs, progressing and regressing WMHs based on baseline and 1-year brain magnetic resonance imaging. In these areas we assessed tissue characteristics with quantitative T1, fractional anisotropy (FA), mean diffusivity (MD), and neurite orientation dispersion and density imaging (baseline only). We compared tissue signatures cross-sectionally between areas, and longitudinally within each area. WMH change masks were available for N=197. Participants' mean age was 65.61 years (SD, 11.10), 59% had a lacunar infarct, and 68% were men. FA and MD were available for N=195, quantitative T1 for N=182, and neurite orientation dispersion and density imaging for N=174. Cross-sectionally, all 4 tissue classes differed for FA, MD, T1, and Neurite Density Index. Longitudinally, in regressing WMHs, FA increased with little change in MD and T1 (difference estimate, 0.011 [95% CI, 0.006-0.017]; -0.002 [95% CI, -0.008 to 0.003] and -0.003 [95% CI, -0.009 to 0.004]); in progressing and stable WMHs, FA decreased (-0.022 [95% CI, -0.027 to -0.017] and -0.009 [95% CI, -0.011 to -0.006]), whereas MD and T1 increased (progressing WMHs, 0.057 [95% CI, 0.050-0.063], 0.058 [95% CI, 0.050 -0.066]; stable WMHs, 0.054 [95% CI, 0.045-0.063], 0.049 [95% CI, 0.039-0.058]); and in stable normal-appearing white matter, MD increased (0.004 [95% CI, 0.003-0.005]), whereas FA and T1 slightly decreased and increased (-0.002 [95% CI, -0.004 to -0.000] and 0.005 [95% CI, 0.001-0.009]). CONCLUSIONS Quantitative magnetic resonance imaging shows that WMHs that regress have less abnormal microstructure at baseline than stable WMHs and follow trajectories indicating tissue improvement compared with stable and progressing WMHs.
Collapse
Affiliation(s)
- Angela C. C. Jochems
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Susana Muñoz Maniega
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Una Clancy
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Carmen Arteaga
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Daniela Jaime Garcia
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Francesca M. Chappell
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Will Hewins
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Rachel Locherty
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Ellen V. Backhouse
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Gayle Barclay
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| | - Charlotte Jardine
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| | - Donna McIntyre
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| | - Iona Gerrish
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| | - Agniete Kampaite
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
| | - Eleni Sakka
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
| | - Maria Valdés Hernández
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Stewart Wiseman
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Mark E. Bastin
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
| | - Michael S. Stringer
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| | - Fergus N. Doubal
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain SciencesUniversity of EdinburghEdinburghUnited Kingdom
- UK Dementia Research Institute at the University of EdinburghEdinburghUnited Kingdom
- Edinburgh Imaging Facility, Royal Infirmary of EdinburghEdinburghUnited Kingdom
| |
Collapse
|
2
|
Kopczak A, Stringer MS, van den Brink H, Kerkhofs D, Blair GW, van Dinther M, Reyes CA, Garcia DJ, Onkenhout L, Wartolowska KA, Thrippleton MJ, Kampaite A, Duering M, Staals J, Lesnik-Oberstein S, Muir KW, Middeke M, Norrving B, Bousser MG, Mansmann U, Rothwell PM, Doubal FN, van Oostenbrugge R, Biessels GJ, Webb AJS, Wardlaw JM, Dichgans M. Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial. Lancet Neurol 2023; 22:991-1004. [PMID: 37863608 DOI: 10.1016/s1474-4422(23)00293-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/15/2023] [Accepted: 08/01/2023] [Indexed: 10/22/2023]
Abstract
BACKGROUND Hypertension is the leading risk factor for cerebral small vessel disease. We aimed to determine whether antihypertensive drug classes differentially affect microvascular function in people with small vessel disease. METHODS We did a multicentre, open-label, randomised crossover trial with blinded endpoint assessment at five specialist centres in Europe. We included participants aged 18 years or older with symptomatic sporadic small vessel disease or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and an indication for antihypertensive treatment. Participants were randomly assigned (1:1:1) to one of three sequences of antihypertensive treatment using a computer-generated multiblock randomisation, stratified by study site and patient group. A 2-week washout period was followed by three 4-week periods of oral monotherapy with amlodipine, losartan, or atenolol at approved doses. The primary endpoint was change in cerebrovascular reactivity (CVR) determined by blood oxygen level-dependent MRI response to hypercapnic challenge in normal-appearing white matter from the end of washout to the end of each treatment period. Efficacy analyses were done by intention-to-treat principles in all randomly assigned participants who had at least one valid assessment for the primary endpoint, and analyses were done separately for participants with sporadic small vessel disease and CADASIL. This trial is registered at ClinicalTrials.gov, NCT03082014, and EudraCT, 2016-002920-10, and is terminated. FINDINGS Between Feb 22, 2018, and April 28, 2022, 75 participants with sporadic small vessel disease (mean age 64·9 years [SD 9·9]) and 26 with CADASIL (53·1 years [7·0]) were enrolled and randomly assigned to treatment. 79 participants (62 with sporadic small vessel disease and 17 with CADASIL) entered the primary efficacy analysis. Change in CVR did not differ between study drugs in participants with sporadic small vessel disease (mean change in CVR 1·8 × 10-4%/mm Hg [SE 20·1; 95% CI -37·6 to 41·2] for amlodipine; 16·7 × 10-4%/mm Hg [20·0; -22·3 to 55·8] for losartan; -7·1 × 10-4%/mm Hg [19·6; -45·5 to 31·1] for atenolol; poverall=0·39) but did differ in patients with CADASIL (15·7 × 10-4%/mm Hg [SE 27·5; 95% CI -38·3 to 69·7] for amlodipine; 19·4 × 10-4%/mm Hg [27·9; -35·3 to 74·2] for losartan; -23·9 × 10-4%/mm Hg [27·5; -77·7 to 30·0] for atenolol; poverall=0·019). In patients with CADASIL, pairwise comparisons showed that CVR improved with amlodipine compared with atenolol (-39·6 × 10-4%/mm Hg [95% CI -72·5 to -6·6; p=0·019) and with losartan compared with atenolol (-43·3 × 10-4%/mm Hg [-74·3 to -12·3]; p=0·0061). No deaths occurred. Two serious adverse events were recorded, one while taking amlodipine (diarrhoea with dehydration) and one while taking atenolol (fall with fracture), neither of which was related to study drug intake. INTERPRETATION 4 weeks of treatment with amlodipine, losartan, or atenolol did not differ in their effects on cerebrovascular reactivity in people with sporadic small vessel disease but did result in differential treatment effects in patients with CADASIL. Whether antihypertensive drug classes differentially affect clinical outcomes in people with small vessel diseases requires further research. FUNDING EU Horizon 2020 programme.
Collapse
Affiliation(s)
- Anna Kopczak
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
| | - Michael S Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Hilde van den Brink
- Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands
| | - Danielle Kerkhofs
- Department of Neurology and School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands
| | - Gordon W Blair
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Maud van Dinther
- Department of Neurology and School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands
| | - Carmen Arteaga Reyes
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Daniela Jaime Garcia
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Laurien Onkenhout
- Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands
| | - Karolina A Wartolowska
- Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Michael J Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Agniete Kampaite
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Marco Duering
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany; Medical Image Analysis Center and Department of Biomedical Engineering, University of Basel, Basel, Switzerland
| | - Julie Staals
- Department of Neurology and School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands
| | | | - Keith W Muir
- School of Psychology and Neuroscience, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK
| | - Martin Middeke
- Hypertoniezentrum München, Excellence Centre of the European Society of Hypertension, Munich, Germany
| | - Bo Norrving
- Department of Clinical Sciences Lund, Neurology, Skåne University Hospital, Lund University, Lund, Sweden
| | | | - Ulrich Mansmann
- Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany
| | - Peter M Rothwell
- Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Fergus N Doubal
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Robert van Oostenbrugge
- Department of Neurology and School for Cardiovascular Diseases, Maastricht University Medical Center+, Maastricht, Netherlands
| | - Geert Jan Biessels
- Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands
| | - Alastair J S Webb
- Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany; Munich Cluster for Systems Neurology, Munich, Germany; German Center for Neurodegenerative Diseases, Munich, Germany; German Centre for Cardiovascular Research, Munich, Germany.
| |
Collapse
|
3
|
Sleight E, Stringer MS, Clancy U, Arteaga C, Jaime Garcia D, Hewins W, Jochems AC, Hamilton OK, Manning C, Morgan AG, Locherty R, Cheng Y, Liu X, Zhang J, Hamilton I, Jardine C, Brown R, Sakka E, Kampaite A, Wiseman S, Valdés-Hernández MC, Chappell FM, Doubal FN, Marshall I, Thrippleton MJ, Wardlaw JM. Cerebrovascular Reactivity in Patients With Small Vessel Disease: A Cross-Sectional Study. Stroke 2023; 54:2776-2784. [PMID: 37814956 PMCID: PMC10589433 DOI: 10.1161/strokeaha.123.042656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 09/06/2023] [Accepted: 09/19/2023] [Indexed: 10/11/2023]
Abstract
BACKGROUND Cerebrovascular reactivity (CVR) is inversely related to white matter hyperintensity severity, a marker of cerebral small vessel disease (SVD). Less is known about the relationship between CVR and other SVD imaging features or cognition. We aimed to investigate these cross-sectional relationships. METHODS Between 2018 and 2021 in Edinburgh, we recruited patients presenting with lacunar or cortical ischemic stroke, whom we characterized for SVD features. We measured CVR in subcortical gray matter, normal-appearing white matter, and white matter hyperintensity using 3T magnetic resonance imaging. We assessed cognition using Montreal Cognitive Assessment. Statistical analyses included linear regression models with CVR as outcome, adjusted for age, sex, and vascular risk factors. We reported regression coefficients with 95% CIs. RESULTS Of 208 patients, 182 had processable CVR data sets (median age, 68.2 years; 68% men). Although the strength of association depended on tissue type, lower CVR in normal-appearing tissues and white matter hyperintensity was associated with larger white matter hyperintensity volume (BNAWM=-0.0073 [95% CI, -0.0133 to -0.0014] %/mm Hg per 10-fold increase in percentage intracranial volume), more lacunes (BNAWM=-0.00129 [95% CI, -0.00215 to -0.00043] %/mm Hg per lacune), more microbleeds (BNAWM=-0.00083 [95% CI, -0.00130 to -0.00036] %/mm Hg per microbleed), higher deep atrophy score (BNAWM=-0.00218 [95% CI, -0.00417 to -0.00020] %/mm Hg per score point increase), higher perivascular space score (BNAWM=-0.0034 [95% CI, -0.0066 to -0.0002] %/mm Hg per score point increase in basal ganglia), and higher SVD score (BNAWM=-0.0048 [95% CI, -0.0075 to -0.0021] %/mm Hg per score point increase). Lower CVR in normal-appearing tissues was related to lower Montreal Cognitive Assessment without reaching convention statistical significance (BNAWM=0.00065 [95% CI, -0.00007 to 0.00137] %/mm Hg per score point increase). CONCLUSIONS Lower CVR in patients with SVD was related to more severe SVD burden and worse cognition in this cross-sectional analysis. Longitudinal analysis will help determine whether lower CVR predicts worsening SVD severity or vice versa. REGISTRATION URL: https://www.isrctn.com; Unique identifier: ISRCTN12113543.
Collapse
Affiliation(s)
- Emilie Sleight
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Michael S. Stringer
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Una Clancy
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Carmen Arteaga
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Daniela Jaime Garcia
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Will Hewins
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Angela C.C. Jochems
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Olivia K.L. Hamilton
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Cameron Manning
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Alasdair G. Morgan
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Rachel Locherty
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Yajun Cheng
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- Department of Neurology, West China Hospital of Sichuan University, Chengdu (Y.C.)
| | - Xiaodi Liu
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- Department of Medicine, University of Hong Kong (X.L.)
| | - Junfang Zhang
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, China (J.Z.)
| | - Iona Hamilton
- Edinburgh Imaging Facility RIE (I.H., C.J., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Charlotte Jardine
- Edinburgh Imaging Facility RIE (I.H., C.J., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Rosalind Brown
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Eleni Sakka
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Agniete Kampaite
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Stewart Wiseman
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Maria C. Valdés-Hernández
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Francesca M. Chappell
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Fergus N. Doubal
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Ian Marshall
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- Edinburgh Imaging Facility RIE (I.H., C.J., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain Sciences (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- UK Dementia Research Institute (E. Sleight, M.S.S., U.C., C.A., D.J.G., W.H., A.C.C.J., O.K.L.H., C.M., A.G.M., R.L., Y.C., X.L., J.Z., R.B., E. Sakka, A.K., S.W., M.C.V.-H., F.M.C., F.N.D., I.M., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
- Edinburgh Imaging Facility RIE (I.H., C.J., M.J.T., J.M.W.), University of Edinburgh, United Kingdom
| |
Collapse
|
4
|
Sri S, Greenstein A, Granata A, Collcutt A, Jochems ACC, McColl BW, Castro BD, Webber C, Reyes CA, Hall C, Lawrence CB, Hawkes C, Pegasiou-Davies CM, Gibson C, Crawford CL, Smith C, Vivien D, McLean FH, Wiseman F, Brezzo G, Lalli G, Pritchard HAT, Markus HS, Bravo-Ferrer I, Taylor J, Leiper J, Berwick J, Gan J, Gallacher J, Moss J, Goense J, McMullan L, Work L, Evans L, Stringer MS, Ashford MLJ, Abulfadl M, Conlon N, Malhotra P, Bath P, Canter R, Brown R, Ince S, Anderle S, Young S, Quick S, Szymkowiak S, Hill S, Allan S, Wang T, Quinn T, Procter T, Farr TD, Zhao X, Yang Z, Hainsworth AH, Wardlaw JM. A multi-disciplinary commentary on preclinical research to investigate vascular contributions to dementia. Cereb Circ Cogn Behav 2023; 5:100189. [PMID: 37941765 PMCID: PMC10628644 DOI: 10.1016/j.cccb.2023.100189] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 09/27/2023] [Accepted: 10/05/2023] [Indexed: 11/10/2023]
Abstract
Although dementia research has been dominated by Alzheimer's disease (AD), most dementia in older people is now recognised to be due to mixed pathologies, usually combining vascular and AD brain pathology. Vascular cognitive impairment (VCI), which encompasses vascular dementia (VaD) is the second most common type of dementia. Models of VCI have been delayed by limited understanding of the underlying aetiology and pathogenesis. This review by a multidisciplinary, diverse (in terms of sex, geography and career stage), cross-institute team provides a perspective on limitations to current VCI models and recommendations for improving translation and reproducibility. We discuss reproducibility, clinical features of VCI and corresponding assessments in models, human pathology, bioinformatics approaches, and data sharing. We offer recommendations for future research, particularly focusing on small vessel disease as a main underpinning disorder.
Collapse
Affiliation(s)
- Sarmi Sri
- UK Dementia Research Institute Headquarters, 6th Floor Maple House, London W1T 7NF, UK
| | - Adam Greenstein
- Division of Cardiovascular Sciences, The University of Manchester, Manchester M13 9PL, UK
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
| | - Alessandra Granata
- Department of Clinical Neurosciences, Victor Phillip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Papworth Road, Cambridge Biomedical Campus, Cambridge CB2 0BB, UK
| | - Alex Collcutt
- UK Dementia Research Institute Headquarters, 6th Floor Maple House, London W1T 7NF, UK
| | - Angela C C Jochems
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Barry W McColl
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Blanca Díaz Castro
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Caleb Webber
- UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, UK
| | - Carmen Arteaga Reyes
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Catherine Hall
- School of Psychology and Sussex Neuroscience, University of Sussex, Falmer, Brighton, East Sussex, UK
| | - Catherine B Lawrence
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
- Division of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Cheryl Hawkes
- Biomedical and Life Sciences, Lancaster University, Lancaster, UK
| | | | - Claire Gibson
- School of Psychology, University of Nottingham, Nottingham NG7 2UH, UK
| | - Colin L Crawford
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Colin Smith
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Denis Vivien
- Physiopathology and Imaging of Neurological Disorders (PhIND), Normandie University, UNICAEN, INSERM UMR-S U1237, , GIP Cyceron, Institute Blood and Brain @ Caen-Normandie (BB@C), Caen, France
- Department of clinical research, Caen-Normandie University Hospital, Caen, France
| | - Fiona H McLean
- Division of Systems Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK
| | - Frances Wiseman
- UK Dementia Research Institute, University College London, London WC1N 3BG, UK
| | - Gaia Brezzo
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Giovanna Lalli
- UK Dementia Research Institute Headquarters, 6th Floor Maple House, London W1T 7NF, UK
| | - Harry A T Pritchard
- Division of Cardiovascular Sciences, The University of Manchester, Manchester M13 9PL, UK
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
| | - Hugh S Markus
- Stroke Research Group, Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, UK
| | - Isabel Bravo-Ferrer
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Jade Taylor
- Division of Cardiovascular Sciences, The University of Manchester, Manchester M13 9PL, UK
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
| | - James Leiper
- BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
| | - Jason Berwick
- Department of Psychology, University of Sheffield, Sheffield, UK
- Neuroscience Institute, University of Sheffield, Sheffield, UK
- Healthy Lifespan Institute, University of Sheffield, Sheffield, UK
| | - Jian Gan
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - John Gallacher
- Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK
| | - Jonathan Moss
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK
- The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, UK
| | - Jozien Goense
- Neuroscience Program, University of Illinois, Urbana-Champaign, Urbana, IL, USA
- Department of Psychology, University of Illinois, Urbana-Champaign, Champaign, IL, USA
- Department of Bioengineering, University of Illinois, Urbana-Champaign, Urbana, IL, USA
- Beckman Institute for Advanced Science and Technology, University of Illinois, Urbana-Champaign, Urbana, IL, USA
- School of Psychology and Neuroscience, University of Glasgow, UK
| | - Letitia McMullan
- School of Psychology and Sussex Neuroscience, University of Sussex, Falmer, Brighton, East Sussex, UK
| | - Lorraine Work
- School of Cardiovascular & Metabolic Health, College of Medical, Veterinary & Life Sciences, University of Glasgow; Glasgow; UK
| | - Lowri Evans
- Division of Cardiovascular Sciences, The University of Manchester, Manchester M13 9PL, UK
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
| | - Michael S Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
| | - MLJ Ashford
- Division of Systems Medicine, School of Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK
| | - Mohamed Abulfadl
- Dementia Research Group, Department of Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol BS10 5NB, UK
| | - Nina Conlon
- Division of Cardiovascular Sciences, The University of Manchester, Manchester M13 9PL, UK
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
| | - Paresh Malhotra
- Department of Brain Sciences, Imperial College London, London, UK
- Department of Neurology, Imperial College Healthcare NHS Trust, London, UK
- UK Dementia Research Institute Care Research and Technology Centre, Imperial College London and the University of Surrey, UK
| | - Philip Bath
- Stroke Trials Unit, University of Nottingham, Nottingham, UK; Stroke, Medicine Division, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Rebecca Canter
- Dementia Discovery Fund, SV Health Managers LLP, London, UK
| | - Rosalind Brown
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
| | - Selvi Ince
- Dementia Research Group, Department of Clinical Neurosciences, Bristol Medical School, University of Bristol, Bristol BS10 5NB, UK
| | - Silvia Anderle
- School of Psychology and Sussex Neuroscience, University of Sussex, Falmer, Brighton, East Sussex, UK
- Department of Neuroscience, Physiology and Pharmacology, University College London, UK
| | - Simon Young
- Dementias Platform UK, Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK
| | - Sophie Quick
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK
| | - Stefan Szymkowiak
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, UK
| | - Steve Hill
- Centre for Discovery Brain Sciences, Chancellor's Building, The University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Cardiff, Cardiff University, Cardiff CF24 4HQ, UK
| | - Stuart Allan
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
- Division of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Tao Wang
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
- Division of Evolution, Infection and Genomic Sciences, Faculty of Biology Medicine and Health, School of Biological Sciences, The University of Manchester, Manchester, UK
- Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK
| | - Terry Quinn
- College of Medical Veterinary and Life Sciences, University of Glasgow, Scotland, UK
| | - Tessa Procter
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
- Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK
- Royal (Dick) School of Veterinary Studies, The University of Edinburgh, UK
| | - Tracy D Farr
- School of Life Sciences, Physiology, Pharmacology, and Neuroscience Division, Medical School, University of Nottingham, Nottingham NG7 2UH, UK
| | - Xiangjun Zhao
- Division of Evolution, Infection and Genomic Sciences, Faculty of Biology Medicine and Health, School of Biological Sciences, The University of Manchester, Manchester, UK
| | - Zhiyuan Yang
- Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK
| | - Atticus H Hainsworth
- Molecular and Clinical Sciences Research Institute, St George's University of London SW17 0RE, UK
- Department of Neurology, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute Edinburgh, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
5
|
Rudilosso S, Stringer MS, Thrippleton M, Chappell F, Blair GW, Jaime Garcia D, Doubal F, Hamilton I, Janssen E, Kopczak A, Ingrisch M, Kerkhofs D, Backes WH, Staals J, Duering M, Dichgans M, Wardlaw JM. Blood-brain barrier leakage hotspots collocating with brain lesions due to sporadic and monogenic small vessel disease. J Cereb Blood Flow Metab 2023; 43:1490-1502. [PMID: 37132279 PMCID: PMC10414006 DOI: 10.1177/0271678x231173444] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 03/02/2023] [Accepted: 03/21/2023] [Indexed: 05/04/2023]
Abstract
Blood-brain barrier (BBB) is known to be impaired in cerebral small vessel disease (SVD), and is measurable by dynamic-contrast enhancement (DCE)-MRI. In a cohort of 69 patients (42 sporadic, 27 monogenic SVD), who underwent 3T MRI, including DCE and cerebrovascular reactivity (CVR) sequences, we assessed the relationship of BBB-leakage hotspots to SVD lesions (lacunes, white matter hyperintensities (WMH), and microbleeds). We defined as hotspots the regions with permeability surface area product highest decile on DCE-derived maps within the white matter. We assessed factors associated with the presence and number of hotspots corresponding to SVD lesions in multivariable regression models adjusted for age, WMH volume, number of lacunes, and SVD type. We identified hotspots at lacune edges in 29/46 (63%) patients with lacunes, within WMH in 26/60 (43%) and at the WMH edges in 34/60 (57%) patients with WMH, and microbleed edges in 4/11 (36%) patients with microbleeds. In adjusted analysis, lower WMH-CVR was associated with presence and number of hotspots at lacune edges, and higher WMH volume with hotspots within WMH and at WMH edges, independently of the SVD type. In conclusion, SVD lesions frequently collocate with high BBB-leakage in patients with sporadic and monogenic forms of SVD.
Collapse
Affiliation(s)
- Salvatore Rudilosso
- Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Michael S Stringer
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Michael Thrippleton
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Francesca Chappell
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Gordon W Blair
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Daniela Jaime Garcia
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Fergus Doubal
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Iona Hamilton
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - Esther Janssen
- Department of Neurology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands
| | - Anna Kopczak
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
| | - Michael Ingrisch
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Danielle Kerkhofs
- Department of Neurology and School for Cardiovascular Diseases (CARIM), Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Walter H Backes
- Department of Radiology & Nuclear Medicine, Schools for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, Netherlands
| | - Julie Staals
- Department of Neurology and School for Cardiovascular Diseases (CARIM), Maastricht University Medical Center+, Maastricht, The Netherlands
| | - Marco Duering
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
- Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
- Munich Cluster for Systems Neurology, Munich, Germany
- German Center for Neurodegenerative Diseases, Munich, Germany
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
| | - on behalf of the SVDs@target consortium
- Comprehensive Stroke Center, Department of Neuroscience, Hospital Clinic and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
- Centre for Clinical Brain Sciences, UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK
- Department of Neurology, Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands
- Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
- Department of Neurology and School for Cardiovascular Diseases (CARIM), Maastricht University Medical Center+, Maastricht, The Netherlands
- Department of Radiology & Nuclear Medicine, Schools for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Maastricht, Netherlands
- Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland
- Munich Cluster for Systems Neurology, Munich, Germany
- German Center for Neurodegenerative Diseases, Munich, Germany
| |
Collapse
|
6
|
Kopczak A, Stringer MS, van den Brink H, Kerkhofs D, Blair GW, van Dinther M, Onkenhout L, Wartolowska KA, Thrippleton MJ, Duering M, Staals J, Middeke M, André E, Norrving B, Bousser MG, Mansmann U, Rothwell PM, Doubal FN, van Oostenbrugge R, Biessels GJ, Webb AJS, Wardlaw JM, Dichgans M. The EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases (TREAT-SVDs) trial: Study protocol for a randomised crossover trial. Eur Stroke J 2023; 8:387-397. [PMID: 37021189 PMCID: PMC10069218 DOI: 10.1177/23969873221143570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 11/16/2022] [Indexed: 12/23/2022] Open
Abstract
Background Hypertension is the leading modifiable risk factor for cerebral small vessel diseases (SVDs). Yet, it is unknown whether antihypertensive drug classes differentially affect microvascular function in SVDs. Aims To test whether amlodipine has a beneficial effect on microvascular function when compared to either losartan or atenolol, and whether losartan has a beneficial effect when compared to atenolol in patients with symptomatic SVDs. Design TREAT-SVDs is an investigator-led, prospective, open-label, randomised crossover trial with blinded endpoint assessment (PROBE design) conducted at five study sites across Europe. Patients aged 18 years or older with symptomatic SVD who have an indication for antihypertensive treatment and are suffering from either sporadic SVD and a history of lacunar stroke or vascular cognitive impairment (group A) or CADASIL (group B) are randomly allocated 1:1:1 to one of three sequences of antihypertensive treatment. Patients stop their regular antihypertensive medication for a 2-week run-in period followed by 4-week periods of monotherapy with amlodipine, losartan and atenolol in random order as open-label medication in standard dose. Outcomes The primary outcome measure is cerebrovascular reactivity (CVR) as determined by blood oxygen level dependent brain MRI signal response to hypercapnic challenge with change in CVR in normal appearing white matter as primary endpoint. Secondary outcome measures are mean systolic blood pressure (BP) and BP variability (BPv). Discussion TREAT-SVDs will provide insights into the effects of different antihypertensive drugs on CVR, BP, and BPv in patients with symptomatic sporadic and hereditary SVDs. Funding European Union's Horizon 2020 programme. Trial registration NCT03082014.
Collapse
Affiliation(s)
- Anna Kopczak
- Institute for Stroke and Dementia
Research, University Hospital, LMU Munich, Munich, Germany
| | - Michael S Stringer
- Centre for Clinical Brain Sciences,
University of Edinburgh, Edinburgh, UK
| | - Hilde van den Brink
- Department of Neurology, UMC Utrecht
Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Danielle Kerkhofs
- Department of Neurology and School for
cardiovascular diseases (CARIM), Maastricht University Medical Center+, Maastricht,
The Netherlands
| | - Gordon W Blair
- Centre for Clinical Brain Sciences,
University of Edinburgh, Edinburgh, UK
| | - Maud van Dinther
- Department of Neurology and School for
cardiovascular diseases (CARIM), Maastricht University Medical Center+, Maastricht,
The Netherlands
| | - Laurien Onkenhout
- Department of Neurology, UMC Utrecht
Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Karolina A Wartolowska
- Wolfson Centre for Prevention of Stroke
and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford,
Oxford, UK
| | | | - Marco Duering
- Institute for Stroke and Dementia
Research, University Hospital, LMU Munich, Munich, Germany
- Medical Image Analysis Center (MIAC AG)
and Department of Biomedical Engineering, University of Basel, Basel,
Switzerland
| | - Julie Staals
- Department of Neurology and School for
cardiovascular diseases (CARIM), Maastricht University Medical Center+, Maastricht,
The Netherlands
| | - Martin Middeke
- Hypertoniezentrum München, Excellence
Centre of the European Society of Hypertension (ESH), Munich, Germany
| | - Elisabeth André
- Münchner Studienzentrum, Faculty of
Medicine, Technical University Munich (TUM), Munich, Germany
| | - Bo Norrving
- Neurology, Department of Clinical
Sciences Lund, Lund University, and Neurology, Skåne University Hospital Lund/Malmö,
Sweden
| | | | - Ulrich Mansmann
- Institute for Medical Information
Processing, Biometry, and Epidemiology, LMU Munich, Munich, Germany
| | - Peter M Rothwell
- Wolfson Centre for Prevention of Stroke
and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford,
Oxford, UK
| | - Fergus N Doubal
- Centre for Clinical Brain Sciences,
University of Edinburgh, Edinburgh, UK
| | - Robert van Oostenbrugge
- Department of Neurology and School for
cardiovascular diseases (CARIM), Maastricht University Medical Center+, Maastricht,
The Netherlands
| | - Geert Jan Biessels
- Department of Neurology, UMC Utrecht
Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Alastair JS Webb
- Wolfson Centre for Prevention of Stroke
and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford,
Oxford, UK
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences,
University of Edinburgh, Edinburgh, UK
- UK Dementia Research Institute,
University of Edinburgh, Edinburgh, UK
| | - Martin Dichgans
- Institute for Stroke and Dementia
Research, University Hospital, LMU Munich, Munich, Germany
- Munich Cluster for Systems Neurology
(SyNergy), Munich, Germany
- German Center for Neurodegenerative
Diseases (DZNE), Munich, Germany
| |
Collapse
|
7
|
Sleight E, Stringer MS, Mitchell I, Murphy M, Marshall I, Wardlaw JM, Thrippleton MJ. Cerebrovascular reactivity measurements using 3T BOLD MRI and a fixed inhaled CO 2 gas challenge: Repeatability and impact of processing strategy. Front Physiol 2023; 14:1070233. [PMID: 36814481 PMCID: PMC9939770 DOI: 10.3389/fphys.2023.1070233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Accepted: 01/19/2023] [Indexed: 02/09/2023] Open
Abstract
Introduction: Cerebrovascular reactivity (CVR) measurements using blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) are commonly used to assess the health of cerebral blood vessels, including in patients with cerebrovascular diseases; however, evidence and consensus regarding reliability and optimal processing are lacking. We aimed to assess the repeatability, accuracy and precision of voxel- and region-based CVR measurements at 3 T using a fixed inhaled (FI) CO2 stimulus in a healthy cohort. Methods: We simulated the effect of noise, delay constraints and voxel- versus region-based analysis on CVR parameters. Results were verified in 15 healthy volunteers (28.1±5.5 years, female: 53%) with a test-retest MRI experiment consisting of two CVR scans. CVR magnitude and delay in grey matter (GM) and white matter were computed for both analyses assuming a linear relationship between the BOLD signal and time-shifted end-tidal CO2 (EtCO2) profile. Results: Test-retest repeatability was high [mean (95% CI) inter-scan difference: -0.01 (-0.03, -0.00) %/mmHg for GM CVR magnitude; -0.3 (-1.2,0.6) s for GM CVR delay], but we detected a small systematic reduction in CVR magnitude at scan 2 versus scan 1, accompanied by a greater EtCO2 change [±1.0 (0.4,1.5) mmHg] and lower heart rate [-5.5 (-8.6,-2.4] bpm]. CVR magnitude estimates were higher for voxel- versus region-based analysis [difference in GM: ±0.02 (0.01,0.03) %/mmHg]. Findings were supported by simulation results, predicting a positive bias for voxel-based CVR estimates dependent on temporal contrast-to-noise ratio and delay fitting constraints and an underestimation for region-based CVR estimates. Discussion: BOLD CVR measurements using FI stimulus have good within-day repeatability in healthy volunteers. However, measurements may be influenced by physiological effects and the analysis protocol. Voxel-based analyses should be undertaken with care due to potential for systematic bias; region-based analyses are more reliable in such cases.
Collapse
Affiliation(s)
- Emilie Sleight
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Isla Mitchell
- Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom
| | - Madeleine Murphy
- Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom
| | - Ian Marshall
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom,Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, University of Edinburgh, Edinburgh, United Kingdom,Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh, United Kingdom,*Correspondence: Michael J. Thrippleton,
| |
Collapse
|
8
|
van den Brink H, Kopczak A, Arts T, Onkenhout L, Siero JCW, Zwanenburg JJM, Hein S, Hübner M, Gesierich B, Duering M, Stringer MS, Hendrikse J, Wardlaw JM, Joutel A, Dichgans M, Biessels GJ. CADASIL Affects Multiple Aspects of Cerebral Small Vessel Function on 7T-MRI. Ann Neurol 2023; 93:29-39. [PMID: 36222455 DOI: 10.1002/ana.26527] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 10/05/2022] [Accepted: 10/07/2022] [Indexed: 02/05/2023]
Abstract
OBJECTIVE Cerebral small vessel diseases (cSVDs) are a major cause of stroke and dementia. We used cutting-edge 7T-MRI techniques in patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), to establish which aspects of cerebral small vessel function are affected by this monogenic form of cSVD. METHODS We recruited 23 CADASIL patients (age 51.1 ± 10.1 years, 52% women) and 13 age- and sex-matched controls (46.1 ± 12.6, 46% women). Small vessel function measures included: basal ganglia and centrum semiovale perforating artery blood flow velocity and pulsatility, vascular reactivity to a visual stimulus in the occipital cortex and reactivity to hypercapnia in the cortex, subcortical gray matter, white matter, and white matter hyperintensities. RESULTS Compared with controls, CADASIL patients showed lower blood flow velocity and higher pulsatility index within perforating arteries of the centrum semiovale (mean difference - 0.09 cm/s, p = 0.03 and 0.20, p = 0.009) and basal ganglia (mean difference - 0.98 cm/s, p = 0.003 and 0.17, p = 0.06). Small vessel reactivity to a short visual stimulus was decreased (blood-oxygen-level dependent [BOLD] mean difference -0.21%, p = 0.04) in patients, while reactivity to hypercapnia was preserved in the cortex, subcortical gray matter, and normal appearing white matter. Among patients, reactivity to hypercapnia was decreased in white matter hyperintensities compared to normal appearing white matter (BOLD mean difference -0.29%, p = 0.02). INTERPRETATION Multiple aspects of cerebral small vessel function on 7T-MRI were abnormal in CADASIL patients, indicative of increased arteriolar stiffness and regional abnormalities in reactivity, locally also in relation to white matter injury. These observations provide novel markers of cSVD for mechanistic and intervention studies. ANN NEUROL 2023;93:29-39.
Collapse
Affiliation(s)
- Hilde van den Brink
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Anna Kopczak
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Tine Arts
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Laurien Onkenhout
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Jeroen C W Siero
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, The Netherlands.,Spinoza Centre for Neuroimaging Amsterdam, Amsterdam, The Netherlands
| | - Jaco J M Zwanenburg
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Sandra Hein
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Mathias Hübner
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Benno Gesierich
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.,Medical Image Analysis Center (MIAC AG) and qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland
| | - Marco Duering
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.,Medical Image Analysis Center (MIAC AG) and qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland
| | - Michael S Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, UK
| | - Jeroen Hendrikse
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Joanna M Wardlaw
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, UK
| | - Anne Joutel
- Institute of Psychiatry and Neurosciences of Paris, Université de Paris, Inserm U1266, Paris, France
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.,Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.,German Center for Neurodegenerative Disease (DZNE), Munich, Germany
| | - Geert Jan Biessels
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands
| | | |
Collapse
|
9
|
Sleight E, Stringer MS, Marshall I, Wardlaw JM, Thrippleton MJ. Corrigendum: Cerebrovascular reactivity measurement using magnetic resonance imaging: A systematic review. Front Physiol 2022; 13:1105285. [PMID: 36569753 PMCID: PMC9780690 DOI: 10.3389/fphys.2022.1105285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 11/29/2022] [Indexed: 12/13/2022] Open
Abstract
[This corrects the article DOI: 10.3389/fphys.2021.643468.].
Collapse
Affiliation(s)
- Emilie Sleight
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom,*Correspondence: Michael S. Stringer,
| | - Ian Marshall
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| |
Collapse
|
10
|
Lee H, Ozturk B, Stringer MS, Koundal S, MacIntosh BJ, Rothman D, Benveniste H. Choroid plexus tissue perfusion and blood to CSF barrier function in rats measured with continuous arterial spin labeling. Neuroimage 2022; 261:119512. [PMID: 35882269 PMCID: PMC9969358 DOI: 10.1016/j.neuroimage.2022.119512] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 06/18/2022] [Accepted: 07/22/2022] [Indexed: 02/08/2023] Open
Abstract
The choroid plexus (ChP) of the cerebral ventricles is a source of cerebrospinal fluid (CSF) production and also plays a key role in immune surveillance at the level of blood-to-CSF-barrier (BCSFB). In this study, we quantify ChP blood perfusion and BCSFB mediated water exchange from arterial blood into ventricular CSF using non-invasive continuous arterial spin labelling magnetic resonance imaging (CASL-MRI). Systemic administration of anti-diuretic hormone (vasopressin) was used to validate BCSFB water flow as a metric of choroidal CSF secretory function. To further investigate the coupling between ChP blood perfusion and BCSFB water flow, we characterized the effects of two anesthetic regimens known to have large-scale differential effects on cerebral blood flow. For quantification of ChP blood perfusion a multi-compartment perfusion model was employed, and we discovered that partial volume correction improved measurement accuracy. Vasopressin significantly reduced both ChP blood perfusion and BCSFB water flow. ChP blood perfusion was significantly higher with pure isoflurane anesthesia (2-2.5%) when compared to a balanced anesthesia with dexmedetomidine and low-dose isoflurane (1.0 %), and significant correlation between ChP blood perfusion and BCSFB water flow was observed, however there was no significant difference in BCSFB water flow. In summary, here we introduce a non-invasive, robust, and spatially resolved in vivo imaging platform to quantify ChP blood perfusion as well as BCSFB water flow which can be applied to study coupling of these two key parameters in future clinical translational studies.
Collapse
Affiliation(s)
- Hedok Lee
- Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA.
| | - Burhan Ozturk
- Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA
| | - Michael S Stringer
- Brain Research Imaging Centre and UK Dementia Research Institute, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Sunil Koundal
- Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA
| | - Bradley J MacIntosh
- Department of Medical Biophysics, Faculty of Medicine, University of Toronto, Toronto, Canada
| | - Douglas Rothman
- Departments of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA
| | - Helene Benveniste
- Department of Anesthesiology, Yale School of Medicine, New Haven, CT, USA
| |
Collapse
|
11
|
Barnes A, Ballerini L, Valdés Hernández MDC, Chappell FM, Muñoz Maniega S, Meijboom R, Backhouse EV, Stringer MS, Duarte Coello R, Brown R, Bastin ME, Cox SR, Deary IJ, Wardlaw JM. Topological relationships between perivascular spaces and progression of white matter hyperintensities: A pilot study in a sample of the Lothian Birth Cohort 1936. Front Neurol 2022; 13:889884. [PMID: 36090857 PMCID: PMC9449650 DOI: 10.3389/fneur.2022.889884] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 08/01/2022] [Indexed: 11/13/2022] Open
Abstract
Enlarged perivascular spaces (PVS) and white matter hyperintensities (WMH) are features of cerebral small vessel disease which can be seen in brain magnetic resonance imaging (MRI). Given the associations and proposed mechanistic link between PVS and WMH, they are hypothesized to also have topological proximity. However, this and the influence of their spatial proximity on WMH progression are unknown. We analyzed longitudinal MRI data from 29 out of 32 participants (mean age at baseline = 71.9 years) in a longitudinal study of cognitive aging, from three waves of data collection at 3-year intervals, alongside semi-automatic segmentation masks for PVS and WMH, to assess relationships. The majority of deep WMH clusters were found adjacent to or enclosing PVS (waves-1: 77%; 2: 76%; 3: 69%), especially in frontal, parietal, and temporal regions. Of the WMH clusters in the deep white matter that increased between waves, most increased around PVS (waves-1-2: 73%; 2-3: 72%). Formal statistical comparisons of severity of each of these two SVD markers yielded no associations between deep WMH progression and PVS proximity. These findings may suggest some deep WMH clusters may form and grow around PVS, possibly reflecting the consequences of impaired interstitial fluid drainage via PVS. The utility of these relationships as predictors of WMH progression remains unclear.
Collapse
Affiliation(s)
- Abbie Barnes
- College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom
| | - Lucia Ballerini
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Maria del C. Valdés Hernández
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Francesca M. Chappell
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Susana Muñoz Maniega
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Rozanna Meijboom
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Ellen V. Backhouse
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Roberto Duarte Coello
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Rosalind Brown
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Mark E. Bastin
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Simon R. Cox
- Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom
| | - Ian J. Deary
- Department of Psychology, University of Edinburgh, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Department of Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
12
|
Rudilosso S, Chui E, Stringer MS, Thrippleton M, Chappell F, Blair GW, Garcia DJ, Doubal F, Hamilton I, Kopczak A, Ingrisch M, Kerkhofs D, Backes WH, Staals J, van Oostenbrugge R, Duering M, Dichgans M, Wardlaw JM. Prevalence and Significance of the Vessel-Cluster Sign on Susceptibility-Weighted Imaging in Patients With Severe Small Vessel Disease. Neurology 2022; 99:e440-e452. [PMID: 35606147 PMCID: PMC9421604 DOI: 10.1212/wnl.0000000000200614] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 03/15/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Magnetic resonance susceptibility-weighted imaging (SWI) can identify small brain blood vessels that contain deoxygenated blood due to its induced magnetic field disturbance. We observed focal clusters of possible dilated small vessels on SWI in white matter in severe small vessel disease (SVD). We assessed their prevalence, associations with SVD lesions, and vascular reactivity in patients with sporadic SVD and in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). METHODS Secondary cross-sectional analysis of a prospective multicenter observational study of patients with either sporadic SVD or CADASIL (INVESTIGATE-SVD) studied with 3 Tesla MRI including blood-oxygen-level-dependent MRI cerebrovascular reactivity (CVR). Two independent raters evaluated SWI sequences to identify "vessel-clusters" in white matter as focal low-signal dots/lines with small vessel appearance (interrater agreement, kappa statistic = 0.66). We assessed per-patient and per-cluster associations with SVD lesion type and severity on structural MRI sequences. We also assessed CVR within and at 2-voxel concentric intervals around the vessel-clusters using contralateral volumes as a reference. RESULTS Among the 77 patients enrolled, 76 had usable SWI sequences, 45 with sporadic SVD (mean age 64 years [SD 11], 26 men [58%]) and 31 with CADASIL (53 years [11], 15 men [48%]). We identified 94 vessel-clusters in 36 of the 76 patients (15/45 sporadic SVD, 21/31 CADASIL). In covariate-adjusted analysis, patients with vessel-clusters had more lacunes (OR, 95% CI) (1.30, 1.05-1.62), higher white matter hyperintensity (WMH) volume (per-log10 increase, 1.92, 1.04-3.56), and lower CVR in normal appearing white matter (per %/mm Hg, 0.77, 0.60-0.99), compared with patients without vessel-clusters. Fifty-seven of the 94 vessel-clusters (61%) corresponded to noncavitated or partially cavitated WMH on fluid-attenuated inversion recovery, and 37 of 94 (39%) to complete cavities. CVR magnitude was lower than in the corresponding contralateral volumes (mean difference [SD], t, p) within vessel-cluster volumes (-0.00046 [0.00088], -3.021, 0.005) and in the surrounding volume expansion shells up to 4 voxels (-0.00011 [0.00031], -2.140, 0.039; -0.00010 [0.00027], -2.295, 0.028) in vessel-clusters with complete cavities, but not in vessel-clusters without complete cavitation. DISCUSSION Vessel-clusters might correspond to maximally dilated vessels in white matter that are approaching complete tissue injury and cavitation. The pathophysiologic significance of this new feature warrants further longitudinal investigation.
Collapse
Affiliation(s)
- Salvatore Rudilosso
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Ernest Chui
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Michael S Stringer
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Michael Thrippleton
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Francesca Chappell
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Gordon W Blair
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Daniela Jaime Garcia
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Fergus Doubal
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Iona Hamilton
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Anna Kopczak
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Michael Ingrisch
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Danielle Kerkhofs
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Walter H Backes
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Julie Staals
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Robert van Oostenbrugge
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Marco Duering
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Martin Dichgans
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany
| | - Joanna M Wardlaw
- From the Comprehensive Stroke Center (S.R.), Department of Neuroscience, Hospital Clinic, University of Barcelona; August Pi i Sunyer Biomedical Research Institute (IDIBAPS)(S.R.), Barcelona, Spain; Centre for Clinical Brain Sciences (E.C., M.S.S., M.T., F.C., G.B., D.J.G., F.D., I.H., J.M.W.), UK Dementia Research Institute, University of Edinburgh, United Kingdom; Institute for Stroke and Dementia Research (A.K., M. Dichgans), University Hospital, LMU Munich; Department of Radiology (M.I.),Ludwig-Maximilians-University Hospital Munich, Germany; Department of Neurology (D.K., J.S., R.v.O.), CARIM-School for Cardiovascular Diseases Maastricht University Medical Center+, Maastricht,; Department of Radiology & Nuclear Medicine (W.H.B.), School for Mental Health & Neuroscience and School for Cardiovascular Diseases, Maastricht University Medical Centre, Netherlands; Institute for Stroke and Dementia Research (ISD) (M. Duering), University Hospital, LMU Munich, Germany; Medical Image Analysis Center (MIAC AG) and Department of Biomedical Engineering (M. Duering), University of Basel, Switzerland; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Center for Neurodegenerative Diseases (DZNE) (M. Dichgans), Munich, Germany.
| |
Collapse
|
13
|
Stringer MS, Heye AK, Armitage PA, Chappell F, Valdés Hernández MDC, Makin SDJ, Sakka E, Thrippleton MJ, Wardlaw JM. Tracer kinetic assessment of blood-brain barrier leakage and blood volume in cerebral small vessel disease: Associations with disease burden and vascular risk factors. Neuroimage Clin 2022; 32:102883. [PMID: 34911189 PMCID: PMC8607271 DOI: 10.1016/j.nicl.2021.102883] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 11/16/2021] [Indexed: 12/01/2022]
Abstract
Permeability surface area (PS) was higher, even in normal appearing tissue. PS was higher in patients with more white matter hyperintensities. Tissue damage affecting vascular surface area may affect how we interpret tracer kinetic results.
Subtle blood–brain barrier (BBB) permeability increases have been shown in small vessel disease (SVD) using various analysis methods. Following recent consensus recommendations, we used Patlak tracer kinetic analysis, considered optimal in low permeability states, to quantify permeability-surface area product (PS), a BBB leakage estimate, and blood plasma volume (vP) in 201 patients with SVD who underwent dynamic contrast-enhanced MRI scans. We ran multivariable regression models with a quantitative or qualitative metric of white matter hyperintensity (WMH) severity, demographic and vascular risk factors. PS increased with WMH severity in grey (B = 0.15, Confidence Interval (CI): [0.001,0.299], p = 0.049) and normal-appearing white matter (B = 0.015, CI: [−0.008,0.308], p = 0.062). Patients with more severe WMH had lower vP in WMH (B = -0.088, CI: [−0.138,-0.039], p < 0.001), but higher vP in normal-appearing white matter (B = 0.031, CI: [−0.004,0.065], p = 0.082). PS and vP were lower at older ages in WMH, grey and white matter. We conclude higher PS in normal-appearing tissue with more severe WMH suggests impaired BBB integrity beyond visible lesions indicating that the microvasculature is compromised in normal-appearing white matter and WMH. BBB dysfunction is an important mechanism in SVD, but associations with clinical variables are complex and underlying damage affecting vascular surface area may alter interpretation of tracer kinetic results.
Collapse
Affiliation(s)
- Michael S Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Anna K Heye
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK
| | - Paul A Armitage
- Academic Unit of Radiology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK
| | - Francesca Chappell
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Maria Del C Valdés Hernández
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK
| | | | - Eleni Sakka
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK
| | - Michael J Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK.
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK DRI at the University of Edinburgh, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
14
|
Jochems ACC, Muñoz Maniega S, Del C Valdés Hernández M, Barclay G, Anblagan D, Ballerini L, Meijboom R, Wiseman S, Taylor AM, Corley J, Chappell FM, Backhouse EV, Stringer MS, Dickie DA, Bastin ME, Deary IJ, Cox SR, Wardlaw JM. Contribution of white matter hyperintensities to ventricular enlargement in older adults. Neuroimage Clin 2022; 34:103019. [PMID: 35490587 PMCID: PMC9062739 DOI: 10.1016/j.nicl.2022.103019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Revised: 03/24/2022] [Accepted: 04/23/2022] [Indexed: 11/16/2022]
Abstract
Lateral ventricles might increase due to generalized tissue loss related to brain atrophy. Alternatively, they may expand into areas of tissue loss related to white matter hyperintensities (WMH). We assessed longitudinal associations between lateral ventricle and WMH volumes, accounting for total brain volume, blood pressure, history of stroke, cardiovascular disease, diabetes and smoking at ages 73, 76 and 79, in participants from the Lothian Birth Cohort 1936, including MRI data from all available time points. Lateral ventricle volume increased steadily with age, WMH volume change was more variable. WMH volume decreased in 20% and increased in remaining subjects. Over 6 years, lateral ventricle volume increased by 3% per year of age, 0.1% per mm Hg increase in blood pressure, 3.2% per 1% decrease of total brain volume, and 4.5% per 1% increase of WMH volume. Over time, lateral ventricle volumes were 19% smaller in women than men. Ventricular and WMH volume changes are modestly associated and independent of general brain atrophy, suggesting that their underlying processes do not fully overlap.
Collapse
Affiliation(s)
- Angela C C Jochems
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK
| | - Susana Muñoz Maniega
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Maria Del C Valdés Hernández
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Gayle Barclay
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Devasuda Anblagan
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Lucia Ballerini
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Rozanna Meijboom
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Stewart Wiseman
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Adele M Taylor
- Lothian Birth Cohorts Group, The University of Edinburgh, UK; Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - Janie Corley
- Lothian Birth Cohorts Group, The University of Edinburgh, UK; Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - Francesca M Chappell
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Ellen V Backhouse
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Michael S Stringer
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK
| | - David Alexander Dickie
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, Queen Elizabeth University Hospital, University of Glasgow, Glasgow, UK
| | - Mark E Bastin
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK
| | - Ian J Deary
- Lothian Birth Cohorts Group, The University of Edinburgh, UK; Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - Simon R Cox
- Lothian Birth Cohorts Group, The University of Edinburgh, UK; Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - Joanna M Wardlaw
- Neuroimaging Sciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at the University of Edinburgh, Edinburgh, UK; Lothian Birth Cohorts Group, The University of Edinburgh, UK.
| |
Collapse
|
15
|
Blair GW, Janssen E, Stringer MS, Thrippleton MJ, Chappell F, Shi Y, Hamilton I, Flaherty K, Appleton JP, Doubal FN, Bath PM, Wardlaw JM. Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial. Stroke 2021; 53:29-33. [PMID: 34847709 PMCID: PMC8700302 DOI: 10.1161/strokeaha.121.034866] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Supplemental Digital Content is available in the text. Cerebral small vessel disease—a major cause of stroke and dementia—is associated with cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone or in combination, improved magnetic resonance imaging–measured cerebrovascular function in patients with lacunar ischemic stroke.
Collapse
Affiliation(s)
- Gordon W Blair
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Esther Janssen
- Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Donders Centre for Medical Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands (E.J.)
| | - Michael S Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Michael J Thrippleton
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Francesca Chappell
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Yulu Shi
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Iona Hamilton
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Katie Flaherty
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (K.F., J.P.A., P.M.B.)
| | - Jason P Appleton
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (K.F., J.P.A., P.M.B.).,Stroke, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, United Kingdom (J.P.A.)
| | - Fergus N Doubal
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| | - Philip M Bath
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (K.F., J.P.A., P.M.B.).,Stroke, Queen's Medical Centre Campus, Nottingham University Hospitals NHS Trust, United Kingdom (P.M.B.)
| | - Joanna M Wardlaw
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.)
| |
Collapse
|
16
|
Jiménez-Sánchez L, Hamilton OKL, Clancy U, Backhouse EV, Stewart CR, Stringer MS, Doubal FN, Wardlaw JM. Sex Differences in Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis. Front Neurol 2021; 12:756887. [PMID: 34777227 PMCID: PMC8581736 DOI: 10.3389/fneur.2021.756887] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 10/04/2021] [Indexed: 01/12/2023] Open
Abstract
Background: Cerebral small vessel disease (SVD) is a common cause of stroke, mild cognitive impairment, dementia and physical impairments. Differences in SVD incidence or severity between males and females are unknown. We assessed sex differences in SVD by assessing the male-to-female ratio (M:F) of recruited participants and incidence of SVD, risk factor presence, distribution, and severity of SVD features. Methods: We assessed four recent systematic reviews on SVD and performed a supplementary search of MEDLINE to identify studies reporting M:F ratio in covert, stroke, or cognitive SVD presentations (registered protocol: CRD42020193995). We meta-analyzed differences in sex ratios across time, countries, SVD severity and presentations, age and risk factors for SVD. Results: Amongst 123 relevant studies (n = 36,910 participants) including 53 community-based, 67 hospital-based and three mixed studies published between 1989 and 2020, more males were recruited in hospital-based than in community-based studies [M:F = 1.16 (0.70) vs. M:F = 0.79 (0.35), respectively; p < 0.001]. More males had moderate to severe SVD [M:F = 1.08 (0.81) vs. M:F = 0.82 (0.47) in healthy to mild SVD; p < 0.001], and stroke presentations where M:F was 1.67 (0.53). M:F did not differ for recent (2015-2020) vs. pre-2015 publications, by geographical region, or age. There were insufficient sex-stratified data to explore M:F and risk factors for SVD. Conclusions: Our results highlight differences in male-to-female ratios in SVD severity and amongst those presenting with stroke that have important clinical and translational implications. Future SVD research should report participant demographics, risk factors and outcomes separately for males and females. Systematic Review Registration: [PROSPERO], identifier [CRD42020193995].
Collapse
Affiliation(s)
- Lorena Jiménez-Sánchez
- Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Olivia K. L. Hamilton
- Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Una Clancy
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Ellen V. Backhouse
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Catriona R. Stewart
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Fergus N. Doubal
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Edinburgh Dementia Research Centre in the UK Dementia Research Institute, Edinburgh, United Kingdom
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Lothian Birth Cohorts, University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
17
|
Stringer MS, Blair GW, Shi Y, Hamilton I, Dickie DA, Doubal FN, Marshall IM, Thrippleton MJ, Wardlaw JM. A Comparison of CVR Magnitude and Delay Assessed at 1.5 and 3T in Patients With Cerebral Small Vessel Disease. Front Physiol 2021; 12:644837. [PMID: 34149442 PMCID: PMC8207286 DOI: 10.3389/fphys.2021.644837] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 04/15/2021] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Cerebrovascular reactivity (CVR) measures blood flow change in response to a vasoactive stimulus. Impairment is associated with several neurological conditions and can be measured using blood oxygen level-dependent (BOLD) magnetic resonance imaging (MRI). Field strength affects the BOLD signal, but the effect on CVR is unquantified in patient populations. METHODS We recruited patients with minor ischemic stroke and assessed CVR magnitude and delay time at 3 and 1.5 Tesla using BOLD MRI during a hypercapnic challenge. We assessed subcortical gray (GM) and white matter (WM) differences using Wilcoxon signed rank tests and scatterplots. Additionally, we explored associations with demographic factors, WM hyperintensity burden, and small vessel disease score. RESULTS Eighteen of twenty patients provided usable data. At 3T vs. 1.5T: mean CVR magnitude showed less variance (WM 3T: 0.062 ± 0.018%/mmHg, range 0.035, 0.093; 1.5T: 0.057 ± 0.024%/mmHg, range 0.016, 0.094) but was not systematically higher (Wilcoxon signal rank tests, WM: r = -0.33, confidence interval (CI): -0.013, 0.003, p = 0.167); delay showed similar variance (WM 3T: 40 ± 12 s, range: 12, 56; 1.5T: 31 ± 13 s, range 6, 50) and was shorter in GM (r = 0.33, CI: -2, 9, p = 0.164) and longer in WM (r = -0.59, CI: -16, -2, p = 0.010). Patients with higher disease severity tended to have lower CVR at 1.5 and 3T. CONCLUSION Mean CVR magnitude at 3T was similar to 1.5T but showed less variance. GM/WM delay differences may be affected by low signal-to-noise ratio among other factors. Although 3T may reduce variance in CVR magnitude, CVR is readily assessable at 1.5T and reveals comparable associations and trends with disease severity.
Collapse
Affiliation(s)
- Michael S. Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - Gordon W. Blair
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - Yulu Shi
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China
| | - Iona Hamilton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - David A. Dickie
- College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - Fergus N. Doubal
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - Ian M. Marshall
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
- UK Dementia Research Institute at the University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
18
|
Stewart CR, Stringer MS, Shi Y, Thrippleton MJ, Wardlaw JM. Associations Between White Matter Hyperintensity Burden, Cerebral Blood Flow and Transit Time in Small Vessel Disease: An Updated Meta-Analysis. Front Neurol 2021; 12:647848. [PMID: 34017302 PMCID: PMC8129542 DOI: 10.3389/fneur.2021.647848] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2020] [Accepted: 04/01/2021] [Indexed: 12/16/2022] Open
Abstract
Cerebral small vessel disease (SVD) is a major contributor to stroke and dementia, characterized by white matter hyperintensities (WMH) on neuroimaging. WMH are associated with reduced cerebral blood flow (CBF) cross-sectionally, though longitudinal associations remain unclear. We updated a 2016 systematic review, identifying 30 new studies, 27 cross-sectional (n = 2,956) and 3 longitudinal (n = 440). Cross-sectionally, 10/27 new studies (n = 1,019) included sufficient data for meta-analysis, which we meta-analyzed with 24 previously reported studies (n = 1,161), total 34 (n = 2,180). Our meta-analysis showed that patients with lower CBF had worse WMH burden (mean global CBF: standardized mean difference (SMD): −0.45, 95% confidence interval (CI): −0.64, −0.27). Longitudinally, associations between baseline CBF and WMH progression varied: the largest study (5 years, n = 252) found no associations, while another small study (4.5 years, n = 52) found that low CBF in the periventricular WMH penumbra predicted WMH progression. We could not meta-analyse longitudinal studies due to different statistical and methodological approaches. We found that CBF was lower in WMH than in normal-appearing white matter in an additional meta-analysis (5 cross-sectional studies; n = 295; SMD: −1.51, 95% CI: −1.94, −1.07). These findings highlight that relationships between resting CBF and WMH are complex. Further longitudinal studies analyzing regional CBF and subsequent WMH change are required to determine the role of CBF in SVD progression.
Collapse
Affiliation(s)
- Catriona R Stewart
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
| | - Michael S Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.,UK Dementia Research Institute at the University of Edinburgh, Edinburgh Medical School, Edinburgh, United Kingdom
| | - Yulu Shi
- Beijing Tian Tan Hospital Affiliated to Capital Medical University, Beijing, China
| | - Michael J Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.,UK Dementia Research Institute at the University of Edinburgh, Edinburgh Medical School, Edinburgh, United Kingdom
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.,UK Dementia Research Institute at the University of Edinburgh, Edinburgh Medical School, Edinburgh, United Kingdom
| |
Collapse
|
19
|
van den Brink H, Kopczak A, Arts T, Onkenhout L, Siero JC, Zwanenburg JJ, Duering M, Blair GW, Doubal FN, Stringer MS, Thrippleton MJ, Kuijf HJ, de Luca A, Hendrikse J, Wardlaw JM, Dichgans M, Biessels GJ. Zooming in on cerebral small vessel function in small vessel diseases with 7T MRI: Rationale and design of the "ZOOM@SVDs" study. Cereb Circ Cogn Behav 2021; 2:100013. [PMID: 36324717 PMCID: PMC9616370 DOI: 10.1016/j.cccb.2021.100013] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 04/14/2021] [Accepted: 04/15/2021] [Indexed: 06/01/2023]
Abstract
Background Cerebral small vessel diseases (SVDs) are a major cause of stroke and dementia. Yet, specific treatment strategies are lacking in part because of a limited understanding of the underlying disease processes. There is therefore an urgent need to study SVDs at their core, the small vessels themselves. Objective This paper presents the rationale and design of the ZOOM@SVDs study, which aims to establish measures of cerebral small vessel dysfunction on 7T MRI as novel disease markers of SVDs. Methods ZOOM@SVDs is a prospective observational cohort study with two years follow-up. ZOOM@SVDs recruits participants with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL, N = 20), sporadic SVDs (N = 60), and healthy controls (N = 40). Participants undergo 7T brain MRI to assess different aspects of small vessel function including small vessel reactivity, cerebral perforating artery flow, and pulsatility. Extensive work-up at baseline and follow-up further includes clinical and neuropsychological assessment as well as 3T brain MRI to assess conventional SVD imaging markers. Measures of small vessel dysfunction are compared between patients and controls, and related to the severity of clinical and conventional MRI manifestations of SVDs. Discussion ZOOM@SVDs will deliver novel markers of cerebral small vessel function in patients with monogenic and sporadic forms of SVDs, and establish their relation with disease burden and progression. These small vessel markers can support etiological studies in SVDs and may serve as surrogate outcome measures in future clinical trials to show target engagement of drugs directed at the small vessels.
Collapse
Key Words
- ASL, Arterial Spin Labeling
- BOLD, Blood Oxygenation Level-Dependent
- CADASIL
- CADASIL, Cerebral Autosomal Dominant Arteriopathy with Leukoencephalopathy and Subcortical Infarcts
- CDR, Clinical Dementia Rating scale
- CERAD+, Consortium to Establish a Disease Registry for Alzheimer's Disease Plus battery
- CES-D, Center for Epidemiologic Studies Depression Scale
- CO2, Carbon Dioxide
- CSF, Cerebrospinal Fluid
- Cerebral small vessel disease
- DTI, Diffusion Tensor Imaging
- EPIC, European Prospective Investigation into Cancer and Nutrition
- EtCO2, End-tidal Carbon Dioxide
- FLAIR, Fluid Attenuated Inversion Recovery
- FOV, Field Of View
- FWHM, Full-Width-at-Half-Maximum
- GE, Gradient Echo
- GM, Grey Matter
- GPRS, General Packet Radio Service
- HRF, Hemodynamic Response Function
- High field strength MRI
- LMU, Ludwig-Maximilians-Universität
- MMSE, Mini-Mental State Examination
- NAWM, Normal Appearing White Matter
- NIHSS, National Institute for Health Stroke Scale
- PI, Pulsatility Index
- ROI, Region Of Interest
- SPPB, Short Physical Performance Battery
- SVDs, Small Vessel Diseases
- SWI, Susceptibility Weighted Imaging
- Small vessel function
- Sporadic SVD
- Stroke
- TE, Echo Time
- TI, Inversion Time
- TR, Repetition Time
- TSE, Turbo Spin Echo
- UMCU, University Medical Center Utrecht
- Vmax, Maximum velocity
- Vmean, Mean velocity
- Vmin, Minimum velocity
- WM, White Matter
- WMH, White Matter Hyperintensity
- fMRI, Functional Magnetic Resonance Imaging
Collapse
Affiliation(s)
- Hilde van den Brink
- Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3508 GA, the Netherlands
| | - Anna Kopczak
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany
| | - Tine Arts
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Laurien Onkenhout
- Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3508 GA, the Netherlands
| | - Jeroen C.W. Siero
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, the Netherlands
- Spinoza Centre for Neuroimaging Amsterdam, Amsterdam, the Netherlands
| | - Jaco J.M. Zwanenburg
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Marco Duering
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- German Center for Neurodegenerative Disease (DZNE), Munich, Germany
| | - Gordon W. Blair
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Fergus N. Doubal
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Hugo J. Kuijf
- Image Sciences Institute, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Alberto de Luca
- Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3508 GA, the Netherlands
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Jeroen Hendrikse
- Department of Radiology, Center for Image Sciences, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Joanna M. Wardlaw
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Research Institute Centre at the University of Edinburgh, Edinburgh, United Kingdom
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- German Center for Neurodegenerative Disease (DZNE), Munich, Germany
| | - Geert Jan Biessels
- Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3508 GA, the Netherlands
| | | |
Collapse
|
20
|
Sleight E, Stringer MS, Marshall I, Wardlaw JM, Thrippleton MJ. Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review. Front Physiol 2021; 12:643468. [PMID: 33716793 PMCID: PMC7947694 DOI: 10.3389/fphys.2021.643468] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Accepted: 02/01/2021] [Indexed: 12/27/2022] Open
Abstract
Cerebrovascular reactivity (CVR) magnetic resonance imaging (MRI) probes cerebral haemodynamic changes in response to a vasodilatory stimulus. CVR closely relates to the health of the vasculature and is therefore a key parameter for studying cerebrovascular diseases such as stroke, small vessel disease and dementias. MRI allows in vivo measurement of CVR but several different methods have been presented in the literature, differing in pulse sequence, hardware requirements, stimulus and image processing technique. We systematically reviewed publications measuring CVR using MRI up to June 2020, identifying 235 relevant papers. We summarised the acquisition methods, experimental parameters, hardware and CVR quantification approaches used, clinical populations investigated, and corresponding summary CVR measures. CVR was investigated in many pathologies such as steno-occlusive diseases, dementia and small vessel disease and is generally lower in patients than in healthy controls. Blood oxygen level dependent (BOLD) acquisitions with fixed inspired CO2 gas or end-tidal CO2 forcing stimulus are the most commonly used methods. General linear modelling of the MRI signal with end-tidal CO2 as the regressor is the most frequently used method to compute CVR. Our survey of CVR measurement approaches and applications will help researchers to identify good practice and provide objective information to inform the development of future consensus recommendations.
Collapse
Affiliation(s)
- Emilie Sleight
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Michael S. Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom,*Correspondence: Michael S. Stringer
| | - Ian Marshall
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Joanna M. Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| | - Michael J. Thrippleton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom,UK Dementia Research Institute, Edinburgh, United Kingdom
| |
Collapse
|
21
|
Stringer MS, Lee H, Huuskonen MT, MacIntosh BJ, Brown R, Montagne A, Atwi S, Ramirez J, Jansen MA, Marshall I, Black SE, Zlokovic BV, Benveniste H, Wardlaw JM. A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. Transl Stroke Res 2020; 12:15-30. [PMID: 32936435 PMCID: PMC7803876 DOI: 10.1007/s12975-020-00843-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 08/16/2020] [Accepted: 08/19/2020] [Indexed: 12/29/2022]
Abstract
Cerebral small vessel disease (SVD) is a major health burden, yet the pathophysiology remains poorly understood with no effective treatment. Since much of SVD develops silently and insidiously, non-invasive neuroimaging such as MRI is fundamental to detecting and understanding SVD in humans. Several relevant SVD rodent models are established for which MRI can monitor in vivo changes over time prior to histological examination. Here, we critically review the MRI methods pertaining to salient rodent models and evaluate synergies with human SVD MRI methods. We found few relevant publications, but argue there is considerable scope for greater use of MRI in rodent models, and opportunities for harmonisation of the rodent-human methods to increase the translational potential of models to understand SVD in humans. We summarise current MR techniques used in SVD research, provide recommendations and examples and highlight practicalities for use of MRI SVD imaging protocols in pre-selected, relevant rodent models.
Collapse
Affiliation(s)
- Michael S Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.,UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
| | - Hedok Lee
- Department of Anesthesiology, Yale School of Medicine, Yale University, New Haven, CT, USA
| | - Mikko T Huuskonen
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.,Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Bradley J MacIntosh
- Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.,Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Rosalind Brown
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.,UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
| | - Axel Montagne
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.,Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Sarah Atwi
- Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
| | - Joel Ramirez
- Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.,Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada
| | - Maurits A Jansen
- Edinburgh Preclinical Imaging, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
| | - Ian Marshall
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.,UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
| | - Sandra E Black
- Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.,Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, ON, Canada.,Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada
| | - Berislav V Zlokovic
- Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.,Department of Physiology and Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Helene Benveniste
- Department of Anesthesiology, Yale School of Medicine, Yale University, New Haven, CT, USA
| | - Joanna M Wardlaw
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. .,UK Dementia Research Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK.
| |
Collapse
|
22
|
Clancy U, Garcia DJ, Stringer MS, Thrippleton MJ, Valdés-Hernández MC, Wiseman S, Hamilton OK, Chappell FM, Brown R, Blair GW, Hewins W, Sleight E, Ballerini L, Bastin ME, Maniega SM, MacGillivray T, Hetherington K, Hamid C, Arteaga C, Morgan AG, Manning C, Backhouse E, Hamilton I, Job D, Marshall I, Doubal FN, Wardlaw JM. Rationale and design of a longitudinal study of cerebral small vessel diseases, clinical and imaging outcomes in patients presenting with mild ischaemic stroke: Mild Stroke Study 3. Eur Stroke J 2020; 6:81-88. [PMID: 33817338 PMCID: PMC7995323 DOI: 10.1177/2396987320929617] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 04/14/2020] [Indexed: 12/21/2022] Open
Abstract
Background Cerebral small vessel disease is a major cause of dementia and stroke, visible on brain magnetic resonance imaging. Recent data suggest that small vessel disease lesions may be dynamic, damage extends into normal-appearing brain and microvascular dysfunctions include abnormal blood–brain barrier leakage, vasoreactivity and pulsatility, but much remains unknown regarding underlying pathophysiology, symptoms, clinical features and risk factors of small vessel disease. Patients and Methods: The Mild Stroke Study 3 is a prospective observational cohort study to identify risk factors for and clinical implications of small vessel disease progression and regression among up to 300 adults with non-disabling stroke. We perform detailed serial clinical, cognitive, lifestyle, physiological, retinal and brain magnetic resonance imaging assessments over one year; we assess cerebrovascular reactivity, blood flow, pulsatility and blood–brain barrier leakage on magnetic resonance imaging at baseline; we follow up to four years by post and phone. The study is registered ISRCTN 12113543. Summary Factors which influence direction and rate of change of small vessel disease lesions are poorly understood. We investigate the role of small vessel dysfunction using advanced serial neuroimaging in a deeply phenotyped cohort to increase understanding of the natural history of small vessel disease, identify those at highest risk of early disease progression or regression and uncover novel targets for small vessel disease prevention and therapy.
Collapse
Affiliation(s)
- Una Clancy
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Michael S Stringer
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | | | - Stewart Wiseman
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Olivia Kl Hamilton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Rosalind Brown
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Gordon W Blair
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Will Hewins
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Emilie Sleight
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Lucia Ballerini
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Mark E Bastin
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Tom MacGillivray
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | | | - Charlene Hamid
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Carmen Arteaga
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Alasdair G Morgan
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Cameron Manning
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Ellen Backhouse
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Iona Hamilton
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Dominic Job
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Ian Marshall
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Fergus N Doubal
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Joanna M Wardlaw
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
23
|
Jochems ACC, Blair GW, Stringer MS, Thrippleton MJ, Clancy U, Chappell FM, Brown R, Jaime Garcia D, Hamilton OKL, Morgan AG, Marshall I, Hetherington K, Wiseman S, MacGillivray T, Valdés-Hernández MC, Doubal FN, Wardlaw JM. Relationship Between Venules and Perivascular Spaces in Sporadic Small Vessel Diseases. Stroke 2020; 51:1503-1506. [PMID: 32264759 PMCID: PMC7185057 DOI: 10.1161/strokeaha.120.029163] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Supplemental Digital Content is available in the text. Perivascular spaces (PVS) around venules may help drain interstitial fluid from the brain. We examined relationships between suspected venules and PVS visible on brain magnetic resonance imaging.
Collapse
Affiliation(s)
- Angela C C Jochems
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Gordon W Blair
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Michael S Stringer
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Michael J Thrippleton
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Una Clancy
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Francesca M Chappell
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Rosalind Brown
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Daniela Jaime Garcia
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Olivia K L Hamilton
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Alasdair G Morgan
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Ian Marshall
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Kirstie Hetherington
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Stewart Wiseman
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Tom MacGillivray
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Maria C Valdés-Hernández
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Fergus N Doubal
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland
| | - Joanna M Wardlaw
- From the Centre for Clinical Brain Sciences (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., R.B., D.J.G., O.K.L.H., A.G.M., I.M., K.H., S.W., T.M., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,UK Dementia Research Institute (A.C.C.J., G.W.B., M.S.S., M.J.T., U.C., F.M.C., D.J.G., O.K.L.H., S.W., M.C.V.-H., F.N.D., J.M.W.), University of Edinburgh, Scotland.,Centre for Cognitive Ageing and Cognitive Epidemiology (J.M.W.), University of Edinburgh, Scotland
| |
Collapse
|
24
|
Varsou O, Turnbull K, Stringer MS, Fernandes CD, Murray AD, Schwarzbauer C, Macleod MJ. Brain hyperintensities in magnetic resonance imaging of patients with mild acute focal neurology. Neurol Sci 2020; 41:1633-1635. [PMID: 31970577 PMCID: PMC7275935 DOI: 10.1007/s10072-020-04256-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Accepted: 01/15/2020] [Indexed: 11/30/2022]
Abstract
Purpose Hyperintensities are common in neuroimaging scans of patients with mild acute focal neurology. However, their pathogenic role and clinical significance is not well understood. We assessed whether there was an association between hyperintensity score with diagnostic category and clinical assessments/measures. Methods One hundred patients (51 ± 12 years; 45:55 women:men), with symptomatology suggestive of short duration ischemia referred for magnetic resonance imaging, were prospectively recruited in NHS Grampian between 2012 and 2014. Hyperintensities were quantified, on T2 and FLAIR, using the Scheltens score. Results The most frequent diagnosis was minor stroke (33%), migraine (25%) and transient ischemic attack (17%). The mean total Scheltens score was 28.49 ± 11.93 with all participants having various loads of hyperintensities. Statistically significant correlations between hyperintensity scores and clinical assessments/measures (age, systolic blood pressure, pulse pressure, MoCA) at the global level were also reflected regionally. These provide further supporting data in terms of the robustness of the Scheltens scale. Conclusion Hyperintensities could serve as a diagnostic and prognostic imaging biomarker for patients, presenting with mild acute focal neurology, warranting application of automated quantification methods. However, larger cohorts are required to provide a definitive answer especially as this is a heterogenous group of patients. Electronic supplementary material The online version of this article (10.1007/s10072-020-04256-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ourania Varsou
- Anatomy Facility, School of Life Sciences, University of Glasgow, Glasgow, UK.
| | - Katie Turnbull
- Anatomy Facility, School of Life Sciences, University of Glasgow, Glasgow, UK
| | - Michael S Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.,UK Dementia Research Institute at the University of Edinburgh, Edinburgh Medical School, Edinburgh, UK
| | | | - Alison D Murray
- Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK
| | - Christian Schwarzbauer
- Faculty of Applied Sciences & Mechatronics, Munich University of Applied Sciences, Munich, Germany
| | - Mary Joan Macleod
- The Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
| |
Collapse
|
25
|
Blair GW, Appleton JP, Flaherty K, Doubal F, Sprigg N, Dooley R, Richardson C, Hamilton I, Law ZK, Shi Y, Stringer MS, Thrippleton MJ, Boyd J, Shuler K, Bath PM, Wardlaw JM. Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial. EClinicalMedicine 2019; 11:34-43. [PMID: 31317131 PMCID: PMC6611094 DOI: 10.1016/j.eclinm.2019.04.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2018] [Revised: 04/01/2019] [Accepted: 04/02/2019] [Indexed: 11/20/2022] Open
Abstract
BACKGROUND Lacunar stroke, a frequent clinical manifestation of small vessel disease (SVD), differs pathologically from other ischaemic stroke subtypes and has no specific long-term secondary prevention. Licenced drugs, isosorbide mononitrate (ISMN) and cilostazol, have relevant actions to prevent SVD progression. METHODS We recruited independent patients with clinically confirmed lacunar ischaemic stroke without cognitive impairment to a prospective randomised clinical trial, LACunar Intervention-1 (LACI-1). We randomised patients using a central web-based system, 1:1:1:1 with minimisation, to masked ISMN 25 mg bd, cilostazol 100 mg bd, both ISMN and cilostazol started immediately, or both with start delayed. We escalated doses to target over two weeks, sustained for eight weeks. Primary outcome was the proportion achieving target dose. Secondary outcomes included symptoms, safety (haemorrhage, recurrent vascular events), cognition, haematology, vascular function, and neuroimaging. LACI-1 was powered (80%, alpha 0.05) to detect 35% (90% versus 55%) difference between the proportion reaching target dose on one versus both drugs at 55 patients. Registration ISRCTN12580546. FINDINGS LACI-1 enrolled 57 participants between March 2016 and August 2017: 18 (32%) females, mean age 66 (SD 11, range 40-85) years, onset-randomisation 203 (range 6-920) days. Most achieved full (64%) or over half (87%) dose, with no difference between cilostazol vs ISMN, single vs dual drugs. Headache and palpitations increased initially then declined similarly with dual versus single drugs. There was no between-group difference in BP, pulse-wave velocity, haemoglobin or platelet function, but pulse rate was higher (mean difference, MD, 6.4, 95%CI 1.2-11.7, p = 0.02), platelet count higher (MD 35.7, 95%CI 2.8, 68.7, p = 0.03) and white matter hyperintensities reduced more (Chi-square p = 0.007) with cilostazol versus no cilostazol. INTERPRETATION Cilostazol and ISMN are well tolerated when the dose is escalated, without safety concerns, in patients with lacunar stroke. Larger trials with longer term follow-up are justified. FUNDING Alzheimer's Society (AS-PG-14-033).
Collapse
Affiliation(s)
- Gordon W. Blair
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Jason P. Appleton
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
- Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Katie Flaherty
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
| | - Fergus Doubal
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Nikola Sprigg
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
- Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Richard Dooley
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
| | - Carla Richardson
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
| | - Iona Hamilton
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Zhe Kang Law
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
- Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK
- Department of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia
| | - Yulu Shi
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Michael S. Stringer
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Michael J. Thrippleton
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
| | - Julia Boyd
- Edinburgh Clinical Trial's Unit, Usher Institute, University of Edinburgh, UK
| | - Kirsten Shuler
- Office for Patient-Oriented Research, Neurosciences Institute, Penn State, Milton S Hershey Medical Center, Penn State University, College of Medicine, Mail Code SB34, 200 Support Services Building, 500 University Drive, Hershey, PA 17033-0850, USA
| | - Philip M. Bath
- Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
- Stroke, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Joanna M. Wardlaw
- Brain Research Imaging Centre, Centre for Clinical Brain Sciences, 57 Little France Crescent, Edinburgh EH16 4TJ, UK
- Edinburgh Dementia Research Centre in the UK Dementia Research Initiative, UK
- Edinburgh Imaging, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
- Corresponding author at: Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK.
| |
Collapse
|
26
|
Cullen B, Moreton FC, Stringer MS, Krishnadas R, Kalladka D, López-González MR, Santosh C, Schwarzbauer C, Muir KW. Resting state connectivity and cognitive performance in adults with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. J Cereb Blood Flow Metab 2016; 36:981-91. [PMID: 26929239 PMCID: PMC4853844 DOI: 10.1177/0271678x16636395] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Accepted: 01/14/2016] [Indexed: 11/15/2022]
Abstract
Cognitive impairment is an inevitable feature of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), affecting executive function, attention and processing speed from an early stage. Impairment is associated with structural markers such as lacunes, but associations with functional connectivity have not yet been reported. Twenty-two adults with genetically-confirmed CADASIL (11 male; aged 49.8 ± 11.2 years) underwent functional magnetic resonance imaging at rest. Intrinsic attentional/executive networks were identified using group independent components analysis. A linear regression model tested voxel-wise associations between cognitive measures and component spatial maps, and Pearson correlations were performed with mean intra-component connectivity z-scores. Two frontoparietal components were associated with cognitive performance. Voxel-wise analyses showed an association between one component cluster and processing speed (left middle temporal gyrus; peak -48, -18, -14; ZE = 5.65, pFWE corr = 0.001). Mean connectivity in both components correlated with processing speed (r = 0.45, p = 0.043; r = 0.56, p = 0.008). Mean connectivity in one component correlated with faster Trailmaking B minus A time (r = -0.77, p < 0.001) and better executive performance (r = 0.56, p = 0.011). This preliminary study provides evidence for associations between cognitive performance and attentional network connectivity in CADASIL. Functional connectivity may be a useful biomarker of cognitive performance in this population.
Collapse
Affiliation(s)
- Breda Cullen
- Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Fiona C Moreton
- Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK
| | - Michael S Stringer
- Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK
| | - Rajeev Krishnadas
- Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Dheeraj Kalladka
- Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK
| | | | | | - Christian Schwarzbauer
- Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK Faculty of Applied Science and Mechatronics, University of Applied Sciences, Munich, Germany
| | - Keith W Muir
- Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, UK
| |
Collapse
|
27
|
Varsou O, Stringer MS, Fernandes CD, Schwarzbauer C, MacLeod MJ. Stroke recovery and lesion reduction following acute isolated bilateral ischaemic pontine infarction: a case report. BMC Res Notes 2014; 7:728. [PMID: 25322939 PMCID: PMC4203895 DOI: 10.1186/1756-0500-7-728] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Accepted: 10/08/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Although pontine strokes account for a small percentage of all ischaemic events, they can be associated with significant initial disability. These lesions may be missed on computed tomography and therefore magnetic resonance imaging is generally preferred for the assessment of brainstem strokes. The aetiopathogenesis of isolated pontine infarcts, not due to a significant compromise (occlusion or dissection) in the vertebrobasilar territory, still remains to be fully characterised. These strokes present with different symptoms, depending on the lesion location and size, partly reflecting the anatomical variability of the vertebrobasilar vessels. Progressive neurological deterioration is relatively common and has been associated with the extension of such lesions. However, many patients with significant infarcts in the pons will do well in the future and initial diffusion-weighted imaging may not add useful prognostication to the clinical assessment. We discuss here a case where an initially progressive presentation was associated with a marked improvement in both clinical and radiological assessments at 42 days. CASE PRESENTATION A 49-year-old white British man presented with left-sided weakness, incoordination, unsteadiness, cerebellar ataxic dysarthria and dysphonia. A baseline magnetic resonance imaging scan with diffusion-weighted imaging, T1-weighted and T2-weighted sequences showed an acute bilateral pontine infarct. On a repeat scan at 42 days, there was a 57.5% decrease in the size of the lesion on the high-resolution three-dimensional T1-weighted image and a corresponding improvement in the symptoms and the clinical assessments of this patient. The reduction in infarct size was also comparable to the decrease calculated between the baseline diffusion-weighted and the follow-up fluid attenuated inversion recovery sequences. CONCLUSION This case report discusses the significant clinical improvement and corresponding lesion reduction in a patient that presented with worsening neurological symptoms and was diagnosed with acute bilateral ischaemic pontine infarction. Further studies, utilising structural and functional magnetic resonance imaging with follow-up scans, are needed to provide better insights into the underlying aetiopathology and recovery mechanisms of pontine stroke. These will help define the relationship between imaging parameters and outcome allowing for better prognosis along with the development of relevant rehabilitation programs for this group of patients.
Collapse
Affiliation(s)
- Ourania Varsou
- Aberdeen Biomedical Imaging Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
| | | | | | | | | |
Collapse
|